Organogenesis Holdings Inc. (ORGO)Healthcare | Drug Manufacturers - Specialty & Generic | Canton, United States | NasdaqCM
1.21 USD
-0.02
(-1.626%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 1.20 -0.01 (-0.010%) ⇩ (Oct. 13, 2026, 4:36 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:37 a.m. EDT
The investment case for Organogenesis is currently broken by a severe deterioration in profitability and a multi-year structural decline in share price. While the company trades at a low price-to-book ratio, this is a value trap driven by negative operating margins, negative return on equity, and a crushing 57% drop in revenue growth. The balance sheet is fragile, with debt exceeding cash reserves, and the stock has lost more than half its value over the last eight years. There is no dividend to provide income, and the recent price action shows no signs of a recovery, trading well below both its 50-day and 200-day moving averages. The options market confirms this pessimism, with heavy put buying suggesting investors are betting on further losses. Until the company demonstrates a path to profitability and stabilizes its top-line growth, this remains a speculative hold with significant downside risk. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.361919 |
| MSTL | 0.381183 |
| AutoETS | 0.388021 |
| AutoTheta | 0.388092 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 5.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.144 |
| Excess Kurtosis | -0.37 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 23.236 |
| Revenue per Share | 3.586 |
| Market Cap | 155,696,208 |
| Forward P/E | -3.90 |
| Beta | 1.27 |
| Profit Margins | -18.40% |
| Website | https://organogenesis.com |
As of Oct. 10, 2026, 7:37 a.m. EDT: Speculators are overwhelmingly positioned for downside protection rather than upside speculation. Put volume and open interest significantly exceed call volume across all expirations, with deep out-of-the-money puts showing notable open interest relative to calls. This indicates a strong consensus among retail traders that the stock faces further decline, despite the underlying asset being priced near its 52-week low.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6925 |
| Address1 | 85 Dan Road |
| All Time High | 310.9 |
| All Time Low | 1.22 |
| Ask | 1.53 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 710,850 |
| Average Daily Volume3 Month | 756,668 |
| Average Volume | 756,668 |
| Average Volume10Days | 710,850 |
| Beta | 1.269 |
| Bid | 0.8928 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.152 |
| City | Canton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.21 |
| Current Ratio | 3.516 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.24 |
| Day Low | 1.195 |
| Debt To Equity | 23.236 |
| Display Name | Organogenesis |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,908,800 |
| Earnings Call Timestamp Start | 1,793,908,800 |
| Earnings Timestamp | 1,793,908,800 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -9,701,000 |
| Ebitda Margins | -0.02121 |
| Enterprise To Ebitda | -32.617 |
| Enterprise To Revenue | 0.692 |
| Enterprise Value | 316,413,216 |
| Eps Current Year | -1.375 |
| Eps Forward | -0.31 |
| Eps Trailing Twelve Months | -0.83 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.6325 |
| Fifty Day Average Change | -0.4225 |
| Fifty Day Average Change Percent | -0.2588055 |
| Fifty Two Week Change Percent | -69.25 |
| Fifty Two Week High | 7.077 |
| Fifty Two Week High Change | -5.867 |
| Fifty Two Week High Change Percent | -0.8290236 |
| Fifty Two Week Low | 1.195 |
| Fifty Two Week Low Change | 0.014999986 |
| Fifty Two Week Low Change Percent | 0.012552288 |
| Fifty Two Week Range | 1.195 - 7.077 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,483,626,600,000 |
| Float Shares | 61,058,647 |
| Forward Eps | -0.31 |
| Forward P E | -3.903226 |
| Free Cashflow | 28,450,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 854 |
| Fullday Change | -0.029999971 |
| Fullday Change Percent | -2.439022 |
| Fullday Price | 1.21 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.71487 |
| Gross Profits | 327,020,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.4456 |
| Held Percent Institutions | 0.5166 |
| Implied Shares Outstanding | 128,674,548 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts. |
| Long Name | Organogenesis Holdings Inc. |
| Market | us_market |
| Market Cap | 155,696,208 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_294048 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -101,683,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 186,578,094 |
| Number Of Analyst Opinions | 1 |
| Open | 1.24 |
| Operating Cashflow | 31,973,000 |
| Operating Margins | -1.19255 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 781 575 0775 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.82644546 |
| Post Market Price | 1.2 |
| Post Market Time | 1,791,923,772 |
| Previous Close | 1.23 |
| Price Eps Current Year | -0.88000005 |
| Price Hint | 4 |
| Price To Book | 1.0503473 |
| Price To Sales Trailing12 Months | 0.3403538 |
| Profit Margins | -0.18396999 |
| Quick Ratio | 2.581 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.02 |
| Regular Market Change Percent | -1.62601 |
| Regular Market Day High | 1.24 |
| Regular Market Day Low | 1.195 |
| Regular Market Day Range | 1.195 - 1.24 |
| Regular Market Open | 1.24 |
| Regular Market Previous Close | 1.23 |
| Regular Market Price | 1.21 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 706,876 |
| Return On Assets | -0.04106 |
| Return On Equity | -0.2592 |
| Revenue Growth | -0.567 |
| Revenue Per Share | 3.586 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 128,674,548 |
| Shares Percent Shares Out | 0.1166 |
| Shares Short | 15,002,130 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 14,248,296 |
| Short Name | Organogenesis Holdings Inc. |
| Short Percent Of Float | 0.1834 |
| Short Ratio | 22.84 |
| Source Interval | 15 |
| State | MA |
| Symbol | ORGO |
| Target High Price | 2.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 2.0 |
| Target Median Price | 2.0 |
| Total Cash | 46,097,000 |
| Total Cash Per Share | 0.358 |
| Total Debt | 66,950,000 |
| Total Revenue | 457,454,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.83 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.628325 |
| Two Hundred Day Average Change | -1.418325 |
| Two Hundred Day Average Change Percent | -0.5396307 |
| Type Disp | Equity |
| Volume | 706,876 |
| Website | https://organogenesis.com |
| Zip | 2,021 |